Valuation: Cellectar Biosciences, Inc.

Market Cap 20.7M 17.76M 16.58M 15.21M 28.6M 1.98B 29.08M 196M 76.61M 992M 77.72M 76.03M 3.28B P/E 2026 *
-1.07x
P/E 2027 * -1.35x
Enterprise Value 20.7M 17.76M 16.58M 15.21M 28.6M 1.98B 29.08M 196M 76.61M 992M 77.72M 76.03M 3.28B EV / Sales 2026 *
-
EV / Sales 2027 * 2.71x
Free-Float
98.25%
Yield 2026 *
-
Yield 2027 * -
08-18 Cellectar Biosciences, Inc. - Special Call
08-13 Cellectar Biosciences, Inc., Q2 2026 Earnings Call, Aug 13, 2026
08-13 Cellectar Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
06-01 Cellectar Biosciences Highlights New Efficacy Data from Phase 2B Clover Wam Study of Iopofosine I 131 in Relapsed or Refractory Waldenström Macroglobulinemia CI
05-20 Cellectar Biosciences Files for Secondary Offering of Common Shares MT
05-19 Cellectar Biosciences, Inc. Announces Board Changes CI
05-14 Cellectar Biosciences, Inc., Q1 2026 Earnings Call, May 14, 2026
05-14 Cellectar Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
05-06 Cellectar Biosciences, Inc. announced that it has received $30.708034 million in funding from Balyasny Asset Management L.P., Nantahala Capital Management, LLC, Caligan Partners, LP, Janus Henderson Investors US LLC, Silverarc Capital Management, LLC and other investors CI
05-05 Cellectar Biosciences Reports Positive 12-Month Follow-Up Data from Phase 2B Clover Wam Study Demonstrating Durable Responses and Efficacy of Iopofosine I 131 in Relapsed or Refractory Waldenström Macroglobulinemia CI
05-05 Cellectar Biosciences, Inc. Appoints Andrew Gu to Board of Directors CI
04-23 Barinthus Biotherapeutics plc Appoints Douglas Swirsky as Chief Financial Officer, Effective as of May 1, 2026 CI
04-23 Barinthus Biotherapeutics plc Appoints Douglas Swirsky as Principal Accounting Officer, Effective as of May 1, 2026 CI

Last Transcript: Cellectar Biosciences, Inc.

1 day+1.74%
1 week+1.54%
Current month+2.72%
1 month+4.76%
3 months-13.73%
6 months-22.58%
Current year-10.51%
1 week 2.45
Extreme 2.45
2.7
1 month 2.33
Extreme 2.33
2.7
Current year 2.2
Extreme 2.2
4.7
1 year 2.2
Extreme 2.2
6.52
3 years 2.2
Extreme 2.2
133.5
5 years 2.2
Extreme 2.2
327
10 years 2.2
Extreme 2.2
10,410.01
Manager TitleAgeSince
Chief Executive Officer 66 15/06/2015
Director of Finance/CFO 60 28/05/2014
Chief Operating Officer 52 23/02/2022
Director TitleAgeSince
Director/Board Member 69 01/02/2008
Director/Board Member 66 15/06/2015
Chairman 56 01/08/2017
Date Insider Type Main position Quantity % Market Cap.
08/07/26 Free

Director

15,000 0.5603%
08/07/26 Free

Director

15,000 0.5603%
07/07/26 Free

Director

25,000 0.9339%
Change 5-day change 1-year change 3-year change Capi.($)
+1.93%+1.54%-41.33%-94.67% 20.7M
+4.35%+4.57%+81.46%+131.99% 1,093B
+1.28%+5.00%+54.05%+63.67% 653B
+2.68%+6.65%+28.67%+76.68% 458B
+1.80%+0.52%+41.20%+44.48% 355B
+1.24%+2.35%+25.99%+41.24% 294B
+2.07%+2.97%+2.27%+12.89% 248B
+3.83%+6.00%+49.27%+69.22% 230B
+1.05%-0.02%-13.96%-52.51% 203B
+3.32%+8.90%+25.41%+94.84% 178B
Average +2.31%+0.89%+25.30%+38.78% 371.05B
Weighted average by Cap. +2.67%+1.45%+46.69%+73.87%

Financials

2026 *2027 *
Net sales - 7.65M 6.56M 6.13M 5.62M 10.57M 731M 10.74M 72.29M 28.31M 367M 28.72M 28.09M 1.21B
Net income -31.63M -27.13M -25.34M -23.25M -43.71M -3.02B -44.43M -299M -117M -1.52B -119M -116M -5.01B -37.38M -32.06M -29.94M -27.47M -51.65M -3.57B -52.5M -353M -138M -1.79B -140M -137M -5.92B
Net Debt - -
Logo Cellectar Biosciences, Inc.
Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of drugs for treatment of cancer. The Company, through its phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its lead programs are: Iopofosine I 131 (iopofosine), a beta-emitting iodine-131-based program which has been studied extensively; CLR 121225, an actinium-225-based program; and CLR 121125, an iodine-125 Auger-emitting program. Iopofosine evaluation is ongoing in a Phase IIb study in r/r multiple myeloma and central nervous system lymphoma patients and the CLOVER-2 Phase Ib study for pediatric patients with high grade gliomas.
Employees
11
Date Price Change Volume
19/08/26 $2.640 +1.93% 42,885
18/08/26 $2.590 +1.17% 31,344
17/08/26 $2.560 -1.54% 51,051
14/08/26 $2.600 +4.84% 46,622
13/08/26 $2.480 -4.62% 30,388
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.590USD
Average target price
11.50USD
Spread / Average Target
+344.02%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CLRB Stock